Recent Updates — TRAX

On October 19, 2026, First Tracks Biotherapeutics closed its previously announced private placement of 6,106,870 shares of common stock. The company entered into a registration rights agreement with the investors, requiring it to file a resale registration statement within 30 days. This equity issuance provides capital for operations. First Tracks Biotherapeutics operates in the biotechnology industry, focusing on developing novel therapies.

First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 shares of common stock to institutional investors in a private placement priced at $32.75 per share. The transaction is expected to generate approximately $200 million in gross proceeds before fees and expenses. Closing is anticipated on October 19, 2026, subject to customary conditions. Proceeds will fund general corporate purposes, including clinical development of ANB033. Investors include Affinity Asset Advisors, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, and Vestal Point Capital. Placement agents are Leerink Partners, Piper Sandler, UBS Investment Bank, and Wells Fargo Securities.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases.

First Tracks Biotherapeutics announced positive top-line results from the first cohort of its Phase 1b trial for ANB033, an investigational CD122 antagonist, in patients with celiac disease. The study demonstrated that ANB033 achieved statistically significant and clinically meaningful protective effects against gluten-induced intestinal damage and symptoms compared to placebo during a 14-day gluten challenge. Key histologic endpoints showed a +0.49 placebo-adjusted delta in the villus height-to-crypt depth ratio (p=0.009) and a -20.03 delta in intraepithelial lymphocyte density (p<0.001). The treatment was well-tolerated with no serious adverse events observed. The company plans to engage with regulators regarding late-stage development, anticipating the start of a Phase 3 trial in celiac disease in 2027.

First Tracks Biotherapeutics is a clinical-stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases.

First Tracks Biotherapeutics, Inc. entered into a 12-month sublease agreement with AnaptysBio, Inc. for approximately 45,057 rentable square feet of office space in San Diego, California. The agreement includes an option to extend the sublease term for up to two years and a termination right for the Company. First Tracks Biotherapeutics, Inc. is a biotechnology company focused on developing biotherapeutic solutions.